FDA recall record

Granix (tbo-filgrastim) Injection 300 mcg/0.5 mL, Single Dose prefilled syringe, packaged as recall — FDA D-0218-2025

Failed Stability Specifications - 12-month stability test result for one of the known peptides is below the specification limit

Class IIclassification
D-0218-2025official record ID
Feb 12, 2025report date

Recall record at a glance

Official recordD-0218-2025
CategoryDrug Recalls
ClassificationClass II
FDA record statusOngoing
Recalling firmTeva Pharmaceuticals USA, Inc
Report dateFeb 12, 2025
Recall initiation dateJan 10, 2025
Quantity34,636 cartons
LocationParsippany, NJ, United States

Official product description

Granix (tbo-filgrastim) Injection 300 mcg/0.5 mL, Single Dose prefilled syringe, packaged as a) 1 syringe in 1 CARTON, NDC 63459-910-11, Blister NDC 63459-910-12; (b)10 syringes in 1 CARTON, NDC 63459-910-15, Blister NDC 63459-910-12; (c) 1 syringe in 1 CARTON, NDC 63459-910-17 without safety guard and blister, Rx Only, Manufactured by: UAB Teva Baltics, Vilnius, Lithuania. Distributed by Teva Pharmaceuticals USA, Inc. North Wales PA 19454. Product of Israel.

Why the product was recalled

Failed Stability Specifications - 12-month stability test result for one of the known peptides is below the specification limit

Distribution information

Product was distributed nationwide.

How to read the classification

FDA Class II indicates a situation in which use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious consequences is remote. The classification shown here comes from the FDA record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.

Related recall records

Other records from the same recalling company are shown first when available.

DrugApr 29, 2026

Claravis recall — FDA D-0521-2026

Failed Impurities/Degradation Specifications: Out of specification for specific impurity Tretinoin

Class IIFDA: OngoingTeva Pharmaceuticals USA, Inc